ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Submission of Matters to a Vote of Security Holders
On November 4, 2019, Alimera Sciences, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the following proposals were submitted to the stockholders of the Company, as set forth in the Company’s definitive proxy statement on Schedule 14A filed with the SEC on September 27, 2019:
On the record date, there were (a) 71,009,400 shares of common stock outstanding and entitled to vote on the basis of one vote per share and (b) shares of our outstanding Series A Preferred Stock entitled to 8,135,593 votes. Of the 79,144,993 votes that were eligible to be cast by the holders of common stock and Series A Preferred Stock at the Special Meeting, 61,884,674 votes, or approximately 78.2% of the total, were represented at the meeting in person or by proxy, based on estimated preliminary voting results. The preliminary voting results in respect of each matter are set forth below. The voting results are preliminary estimates only and are subject to change. The Company will file an amendment to this Current Report on Form 8-K to disclose the final voting results from the Special Meeting within four business days after the final, certified voting results are known.
About ALIMERA SCIENCES, INC. (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
